LAMBDA-CAP
Live / Registered — Registered — partial invalidation of extension of protection (as of 04 Jun 2026)
What this means for you
Registered since 11 Feb 2020. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 11 Feb 2030: the §71 ten-year affidavit of use).
Record
- Serial number
- 79250615
- Registration number
- 5980170
- Mark type
- Word mark
- Filed
- 03 Dec 2018
- Published for opposition
- 26 Nov 2019
- Registered
- 11 Feb 2020
- Next maintenance filing
- §71 ten-year affidavit of use, due by 11 Feb 2030 (grace period to 11 Aug 2030)
- Attorney of record
- Dennis S. Prahl
Goods and services
- Class 001 — Chemicals: [ Chemical, biochemical, biological and biotechnological products intended for industry and science, namely, biological preparations for use in industry and science, diagnostic preparations for clinical and medical laboratory use; chemical, biochemical, biological and biotechnological products, namely, antibodies and antibody particles for development and manufacture of pharmaceutical products; biological products, namely, antibodies and antibody fragments for use in laboratories, diagnosis and analysis for scientific and research purposes; chemical and biochemical additives, supports and substances for the manufacture of pharmaceutical products ]
- Class 005 — Pharmaceuticals: [ Pharmaceutical and veterinary products, namely, pharmaceutical products for the prevention and treatment of immune system related diseases and disorders, therapeutic vaccines; pharmaceutical preparations, namely, pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases; medicines for human medicine, namely, medicinal preparations for the treatment of infectious diseases and for use in oncology; chemical pharmaceutical products for the diagnosis and treatment of cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases; diagnostic preparations for medical use; chemical preparations for pharmaceutical use namely, for diagnosing and treating cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases ]
- Class 042 — Scientific and technological services: Research and development in the field of pharmaceutical products, biotechnology, antibodies and antibody fragments, proteins, micro-organisms and cells for therapeutic purposes; research with respect to pharmaceutical products, biotechnology, therapy, antibody and gene therapy; research, product development and quality control in the field of pharmacy, diagnostics and therapy; research in the field of chemistry and biology; industrial analysis and research services in the field of biochemistry and pharmaceuticals; research and development of antibody products for therapeutic purposes; preparing and conducting chemical, biochemical and biotechnological analysis and research
Owner
- Numab Therapeutics AG, Wädenswil, CH
- Numab Therapeutics AG, CH
- Numab Therapeutics AG, CH
Prosecution history
- 11 May 2020 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 11 Feb 2020 — REGISTERED-PRINCIPAL REGISTER
- 26 Nov 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Nov 2019 — PUBLISHED FOR OPPOSITION
- 06 Nov 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Oct 2019 — ASSIGNED TO LIE
- 16 Oct 2019 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 Oct 2019 — EXAMINER'S AMENDMENT ENTERED
- 10 Oct 2019 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 10 Oct 2019 — EXAMINERS AMENDMENT E-MAILED
- 10 Oct 2019 — EXAMINERS AMENDMENT -WRITTEN
- 20 Sept 2019 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 20 Sept 2019 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 20 Sept 2019 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 21 Jun 2019 — CHANGE OF NAME/ADDRESS REC'D FROM IB